Abstract:Modeling clinically relevant tissue responses using cell models poses a significant challenge for drug development, in particular for drug induced liver injury (DILI). This is mainly because existing liver models lack longevity and tissue-level complexity which limits their utility in predictive toxicology. In this study, we established and characterized novel bioprinted human liver tissue mimetics comprised of patient-derived hepatocytes and non-parenchymal cells in a defined architecture. Scaffold-free assembly of different cell types in an in vivo-relevant architecture allowed for histologic analysis that revealed distinct intercellular hepatocyte junctions, CD31+ endothelial networks, and desmin positive, smooth muscle actin negative quiescent stellates. Unlike what was seen in 2D hepatocyte cultures, the tissues maintained levels of ATP, Albumin as well as expression and drug-induced enzyme activity of Cytochrome P450s over 4 weeks in culture. To assess the ability of the 3D liver cultures to model tissue-level DILI, dose responses of Trovafloxacin, a drug whose hepatotoxic potential could not be assessed by standard pre-clinical models, were compared to the structurally related non-toxic drug Levofloxacin. Trovafloxacin induced significant, dose-dependent toxicity at clinically relevant doses (≤ 4uM). Interestingly, Trovafloxacin toxicity was observed without lipopolysaccharide stimulation and in the absence of resident macrophages in contrast to earlier reports. Together, these results demonstrate that 3D bioprinted liver tissues can both effectively model DILI and distinguish between highly related compounds with differential profile. Thus, the combination of patient-derived primary cells with bioprinting technology here for the first time demonstrates superior performance in terms of mimicking human drug response in a known target organ at the tissue level.

Multicellular, fluid flow-inclusive hepatic in vitro models using NANOSTACKS™: a human-relevant model for drug response prediction

Synergistic Modulation of a Tunable Microenvironment to Fabricate a Liver Fibrosis Chip for Drug Testing.

Development of novel tools for the in vitro investigation of drug-induced liver injury

Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids

Microfluidic human physiomimetic liver model as a screening platform for drug induced liver injury

A microvascularized in vitro liver model for disease modeling and drug discovery

A 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate®

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Comprehensive Evaluation of Organotypic and Microphysiological Liver Models for Prediction of Drug-Induced Liver Injury

Human Hepatic Spheroid Coculture Model for the Assessment of Drug-Induced Liver Injury.

In Vitro Human Liver Model for Toxicity Assessment with Clinical and Preclinical Instrumentation

Physiological liver microtissue 384-well microplate system for preclinical hepatotoxicity assessment of therapeutic small molecule drugs

Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases

An integrated biomimetic array chip for establishment of collagen‐based 3D primary human hepatocyte model for prediction of clinical drug‐induced liver injury

In Situ Self-Assembling Liver Spheroids with Synthetic Nanoscaffolds for Preclinical Drug Screening Applications

Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILI

Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro

Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury

Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease